Of note, a recent study investigating the role of Ezh2 in a Brca1 deficiency-based model of mammary tumorigenesis found that deletion of Ezh2 shortens the latency of tumor formation (Bae et al. 2015), further reinforcing the view that the enzyme might inhibit breast tumorigenesis. The gene discussed is BRCA1; the disease is neoplasm.